The global hidradenitis suppurativa (HS) treatment market is expected to surpass an impressive valuation of USD 763.6 million in 2023 and is projected to reach USD 1,240.9 million by 2033, expected to register a CAGR of 4.97%.
Revenue growth of the global Hidradenitis suppurativa (HS) treatment market is significantly propelled by factors such as the increasing prevalence of chronic diseases, rapid advancements in the healthcare and medical sector, high adoption of the latest tools and techniques, and increasing funds by several public and private sectors.
In addition, growing focus on drug development, rising demand for precision medicine, high adoption of home care settings and point-of-care diagnostics, and growing investments in research and development activities are anticipated to drive global market revenue growth during the forecast period.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | USD 763.6 million |
Anticipated Forecast Value (2033) | USD 1240.9 million |
Projected Growth Rate (2023 to 2033) | CAGR 4.97% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for Hidradenitis suppurativa (HS) treatment was worth USD 640 million in 2018 while growing at a CAGR of 3.59% during the historical period.
InflaRx's lead drug candidate, vilobelimab (IFX-1), is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Hidradenitis suppurativa (HS) treatment (HS), a chronic debilitating systemic skin disease. The Company received scientific advice from the European Medicines Agency (EMA) about the European pathway for regulatory approval in July 2020. The Company is working diligently to address the feedback received from the agencies and analyzing the strategy for its Phase III development in HS.
Considering the arrival of new drugs and other factors, the industry of Hidradenitis suppurativa (HS) treatment is projected to grow at 4.97% CAGR, reaching USD 1240.9 million by end of the forecast period.
Adoption of pipeline therapies to propel market growth
Adoption of key Hidradenitis suppurativa (HS) treatment pipeline therapies such as Bermekimab (MABp1), IFX-1, INCB054707, Secukinumab, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody, Avacopan, Bimekizumab, and others are under different phases of clinical trials for Hidradenitis suppurativa (HS) treatment. Thus, leading to market expansion during the forecast period.
On the other hand, topline data from the AURORA Phase II clinical trial of Avacopan in Hidradenitis suppurativa (HS) treatment demonstrated a statistically significant higher response with avacopan at 30 mg BID than placebo in the pre-specified Hurley Stage III (severe) Hidradenitis suppurativa (HS) treatment patients, which will further drive market growth.
Moreover, chemoCentryx plans to advance Avacopan into Phase III development for the treatment of patients with the most severe form of Hidradenitis suppurativa (HS) treatment. Thus, augmenting the market growth.
Also, Orismilast, Type 4 cyclic nucleotide phosphodiesterase inhibitors are being developed by Union Therapeutics for psoriasis, atopic dermatitis, and hidradenitis suppurative (HS) treatment which will fuel market expansion during the projected timeline.
High cost of treatment, delay in treatment restraining industry’s growth
The high cost associated with treatment is expected to challenge the growth of the market. Also, the dearth of healthcare infrastructure in developing economies and the delay in the procedure of treatment completion may be due to the unawareness of the disease to physicians.
This will challenge the hidradenitis suppurativa (HS) treatment market. Additionally, the lack of skilled professionals and side effects involved with the treatment will act as restraints and further restrict the growth of the market during the forecast period.
North America dominates the market with the maximum share
The hidradenitis supportive treatment market in North America is expected to garner a valuation of USD 620.4 million with a CAGR of 4.2% during the forecast period. Thus, accounting for 50% market share by end of the forecast period.
The growth is attributable to the surging adoption of newer techniques in this region and the growing presence of major key players and well-established healthcare infrastructure. Furthermore, growth is also driven by factors such as a rise in dermatological infections, an increase in clinical practices, and clinically trained professionals.
East Asia to drive growth at a Steady Pace
The market in East Asia is projected to grow at the fastest CAGR of 5.1% during the forecast period. Growth in the number of generic manufacturers and rising government initiatives in this region are propelling market growth. Also, the development of healthcare infrastructure will further fuel growth in this region.
The rise in inflammatory skin disease, healthcare awareness, and government support are leading to market expansion in this region. Additionally, continuous improvement in the life science industry and health services and the awareness of skin diseases and their treatment are factors contributing to the highest growth of this market.
Moreover, increasing incomes and the purchasing power of citizens are witnessing a significant growth rate in this market which is benefitting the market in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Biologics propelling growth with maximum share
The biologics segment is expected to account for a share of 61.4% by the end of the forecast period. Humira (Abbvie) is the first and only approved drug for Moderate to Severe hidradenitis suppurativa (HS) treatment until now which will lead to the fastest acceleration of this segment.
The growth of the biologics segment is augmented by rising demand for biologics due to high efficacy, rising product approvals, and the availability of a robust pipeline of biologic drugs for hidradenitis suppurative (HS) treatment.
For instance, In July 2015, the European Commission approved Humira to treat moderate to severe hidradenitis suppurative (HS) treatment. Similarly, this drug was approved in the USA in September 2015. Moreover, Humira is the only drug in Japan for hidradenitis suppurative (HS) treatment indication which will drive the growth of this segment in Japan. The unavailability of other alternative drugs and faster approval rate of other biologics similar to ‘Humira’ are expected to fuel the growth of this segment in the forecast period.
Another biologic, ‘Metformin’ is also used to treat metabolic syndrome associated with hidradenitis suppurative (HS) treatment and has been reported to reduce hidradenitis suppurativa (HS) treatment disease activity effectively. This will aid in the segment’s growth during the forecast period.
Hospital pharmacies lead the segment with a significant share
By distribution channel, the hospital pharmacies segment dominated the market in 2022, and this trend is projected to continue during the forecast period. This segment is anticipated to possess around 65% market share by end of 2033.
The growth is attributable to the rise in prices of drugs, rising income levels of poor & middle-class families, and faster approval of drugs. Moreover, an increasing number of initiatives from various governmental bodies in enhancing the infrastructure of hospitals and pharmacies are expected to boost the growth of the hospital pharmacies segment.
The topical route of administration driving growth with maximum share
This segment is anticipated to account for the maximum share of 68.5% by end of the forecast period. As topical medical yielded rapid and significant improvements in patients with moderate to severe hidradenitis suppurative (HS) treatment, it has witnessed higher demand in the hidradenitis suppurativa (HS) treatment market. This trend is most likely to remain the same during the forecast period.
The global Hidradenitis suppurativa (HS) treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
The major players in the market are Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma SPRL, Janssen Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics/Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, and Aristea Therapeutics.
Some recent developments in this industry are:
Report Attribute | Details |
---|---|
Market Value in 2023 | USD 763.6 million |
Market Value in 2033 | USD 1,240.9 million |
Growth Rate | CAGR of 4.97% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
Clinical Stage, Treatment, Route of Administration, End User, Distribution Channel, Region |
Regions Covered |
North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
Key Companies Profiled |
InflaRx N.V; Novartis A.G; Incyte Corporation; UCB Biopharma SPRL; Janssen Pharmaceuticals; Amgen Inc.; ChemoCentryx; Priovant Therapeutics; AnaptysBio; AbbVie Inc.; ACELYRIN; Aclaris Therapeutics Inc.; Boehringer Ingelheim; Eli Lilly and Company; MoonLake Immunotherapeutics; Aristea Therapeutics |
Customization | Available Upon Request |
The regional market to witness an absolute growth opportunity of USD 620.4 million through 2033.
The regional market in East Asia is projected to follow 5.1% growth rate until 2033.
High efficacy and increased product approvals have strengthened this segment.
The hospital pharmacies segment achieves around 65% of the global sales .
The topical route of administration to account for 68.5% of the global market share.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Clinical Stages 5.1. Hurley Stage 1 - Low 5.2. Hurley Stage 2 - Moderate 5.3. Hurley Stage 3 - High 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 6.1. Medication 6.1.1. Biologics 6.1.2. Antibiotics 6.1.3. Hormonal Therapy 6.1.4. Immune Suppurativa Drugs 6.1.5. Zinc Supplements 6.1.6. Pain Medications 6.2. Surgery 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Oral 7.2. Topical 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 8.1. Hospitals 8.2. Homecare 8.3. Specialty Clinics 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Hospital Pharmacy 9.2. Online Pharmacy 9.3. Retail Pharmacy 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. South Asia 10.5. East Asia 10.6. Oceania 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 18. Key Countries Market Analysis 19. Market Structure Analysis 20. Competition Analysis 20.1. InFlaRx N.V 20.2. Novartis A.G. 20.3. Incyte Corporation 20.4. UCB Biopharma SPRL 20.5. Janssen Pharmaceuticals 20.6. Amgen Inc. 20.7. ChemoCentryx 20.8. Priovant Therapeutics 20.9. AnaptysBio 20.10. AbbVie Inc. 20.11. ACELYRIN 20.12. Aclaris Therapeutics Inc. 20.13. Boehringer Ingelheim 20.14. Eli Lilly & Company 20.15. MoonLake Immunotherapeutics 20.16. Aristea Therapeutics 21. Assumptions & Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports